Edition:
United States

Shanghai Fosun Pharmaceutical Group Co Ltd (600196.SS)

600196.SS on Shanghai Stock Exchange

31.04CNY
26 May 2017
Change (% chg)

¥-0.26 (-0.83%)
Prev Close
¥31.30
Open
¥31.23
Day's High
¥31.49
Day's Low
¥30.50
Volume
6,678,299
Avg. Vol
11,180,774
52-wk High
¥32.24
52-wk Low
¥18.25

Latest Key Developments (Source: Significant Developments)

Shanghai Fosun Pharma's controlling shareholder bought H-shares in the company
Wednesday, 24 May 2017 07:33am EDT 

May 24 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>2196.HK:Says controlling shareholder bought 500,000 million H-shares in the company at about HK$29.39 per share on May 24 for about 12.98 million yuan ($1.88 million).Says controlling shareholder holds about 37.7 percent stake in the company after transaction.  Full Article

Shanghai Fosun Pharmaceutical Group Co says Fosun Group acquired an aggregate of 200,000 H shares
Tuesday, 23 May 2017 08:06am EDT 

May 23 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Fosun Group acquired through shanghai-hong kong stock connect trading system of shanghai stock exchange an aggregate number of 200,000 h shares.H shares at average purchase price of approximately hk$29.19 per h share.Total purchase price thereof is approximately rmb5.15 million.As at close on 23 may fosun has increased shareholding of co for an aggregate amount equivalent to rmb68.43 million.Fosun Group proposes to increase its shareholding in co for an aggregate amount not less than rmb70 million within 12 months.Planned increase within 12 months from 9 may of shareholding percentage in aggregate shall not exceed 2% of total issued shares of co.  Full Article

Shanghai Fosun Pharmaceutical enters into placing agreement to place 80.7 million H shares
Tuesday, 16 May 2017 08:36pm EDT 

May 17 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::Entered into placing agreement to place 80.7 million H shares at a price of HK$28.80 per H share.Net proceeds of placing will be approximately HK$2.31 billion.Intends to use net proceeds from placing to repay interest-bearing debts,and finance potential mergers & acquisitions.  Full Article

Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources
Monday, 15 May 2017 01:26pm EDT 

May 15 (Reuters) - :Advent, Shanghai Pharma said to consider rival bid of about 70 euros a share for Stada - Bloomberg, citing sources.  Full Article

Shanghai Fosun Pharma announces increase in shareholding by controlling shareholder
Thursday, 11 May 2017 08:31am EDT 

May 11 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Fosun group acquired an aggregate number of 500,000 H shares at average purchase price of about HK$30.40 per H share.Total purchase price for shares thereof is approximately RMB13.48 million.  Full Article

Shanghai Fosun Pharma announces increase in shareholding by controlling shareholder
Wednesday, 10 May 2017 09:13am EDT 

May 10 (Reuters) - Shanghai Fosun Pharmaceutical 2196.HK:Increase in shareholding by a controlling shareholder .Fosun Group acquired an aggregate number of 240,000 A shares and 500,000 H shares.Total purchase price for shares is RMB20.80 mln.  Full Article

Shanghai Fosun Pharmaceutical updates on increase in shareholding
Tuesday, 9 May 2017 10:30am EDT 

May 9 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Co was notified by controlling shareholder, Shanghai Fosun High Technology Co Ltd that Fosun Group acquired additional A shares and H shares of co.Fosun Group acquired an aggregate of 515,928 A shares & 533,000 H shares.total purchase price for shares is approximately RMB29.01 million.  Full Article

Shanghai Fosun pharmaceutical says unit entered into JV contract
Thursday, 27 Apr 2017 11:22am EDT 

April 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>::Unit, Xingxin Investment, Fosun Golden entered into joint venture contract.Under joint venture contract, Fosun Pingyao, Xingxin Investment And Fosun Golden agreed to establish new company.Registered capital of new co is RMB500 million, fosun pingyao, xingxin investment and fosun golden 20pct, 60pct and 20pct of equity interests respectively.Business scope of new Co includes financial lease, purchasing leased assets from domestic and -2- foreign markets.Fosun Pingyao agreed to make capital contribution into new company in amount of RMB100 million in cash.  Full Article

Shanghai Fosun Pharmaceutical posts qtrly net profit attributable RMB 737.7 million
Thursday, 27 Apr 2017 07:37am EDT 

April 27 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd <600196.SS>:Qtrly net profit attributable RMB 737.7 million versus RMB 634.2 million.Qtrly operating revenue RMB 3.88 billion versus RMB 3.23 billion.  Full Article

Fosun International updates on acquisition of controlling interest in Gland Pharma
Monday, 24 Apr 2017 07:09am EDT 

April 24 (Reuters) - Fosun International Ltd <0656.HK> ::Progress on acquisition of controlling interest in Gland Pharma Limited.Termination date was extended to 27 april 2017 in accordance with share purchase agreement.Fosun Pharma, buyer, KKR, founder shareholders & target co entered into amendment agreement to extend termination date.  Full Article

More From Around the Web